Novel PARP-1 Inhibitor scaffolds disclosed by a dynamic structure-based pharmacophore approach

21Citations
Citations of this article
39Readers
Mendeley users who have this article in their library.

Abstract

PARP-1 inhibition has been studied over the last decades for the treatment of various diseases. Despite the fact that several molecules act as PARP-1 inhibitors, a reduced number of compounds are used in clinical practice. To identify new compounds with a discriminatory PARP-1 inhibitory function, explicit-solvent molecular dynamics simulations using different inhibitors bound to the PARP-1 catalytic domain were performed. The representative structures obtained were used to generate structure-based pharmacophores, taking into account the dynamic features of receptor-ligand interactions. Thereafter, a virtual screening of compound databases using the pharmacophore models obtained was performed and the hits retrieved were subjected to molecular docking-based scoring. The drug-like molecules featuring the best ranking were evaluated for their PARP-1 inhibitory activity and IC50 values were calculated for the top scoring docked compounds. Altogether, three new PARP-1 inhibitor chemotypes were identified.

Cite

CITATION STYLE

APA

Baptista, S. J., Silva, M. M. C., Moroni, E., Meli, M., Colombo, G., Dinis, T. C. P., & Salvador, J. A. R. (2017). Novel PARP-1 Inhibitor scaffolds disclosed by a dynamic structure-based pharmacophore approach. PLoS ONE, 12(1). https://doi.org/10.1371/journal.pone.0170846

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free